Pfizer Inc's (NYSE:PFE) deal with Washington isn't just a handshake in the Oval Office — it's a seismic jolt to America's drug-pricing game. By agreeing to sell medicines on the government's new TrumpRx platform at steep discounts and extend "most favored nation" (MFN) pricing to Medicaid, Pfizer bought itself a three-year tariff reprieve and plenty of goodwill. But the ripple effects could redraw the profit map for insurers, pharmacies, and rival drugmakers.Track PFE stock here.Now, three household names — ...

Ah, the stock market. A fickle beast, swayed by everything from geopolitical tremors to a rogue tweet. But in the grand theater of financial volatility, one performer consistently delivers a unique brand of drama: Donald J. Trump. With a recent flurry of pronouncements, from cinematic tariffs to pharmaceutical pacts, the former (and potentially future) President has once again reminded us that when it comes to market reactions, predictability is, well, entirely unpredictable. It’s a high-stakes game of poli ...

Americans will soon be able to buy prescription drugs directly from the federal government, according to the White House. On Tuesday, President Donald Trump announced the launch of a direct-to-consumer website where consumers could purchase discounted drugs. It will be called "TrumpRx.""It increases transparency; in many instances, prices are 80% lower than they are today," Chris Klomp, the Director of Medicare and Deputy Administrator of CMS, said during the announcement. "No more Canadian detours to purc ...